TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00573014

Intervention type: OTHER
Intervention: Cervical Spine Clearance
Description: All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
Study: NCT02249039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent IV CLON
Description: Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
Study: NCT05636761

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability
Description: Collection and Analysis of Heart Rate Variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability
Description: Collection and Analysis of Heart Rate Variability
Study: NCT03162419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: High volume plasma exchange sessions till a maximum of ten sessions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF
Description: The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF
Description: The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
Study: NCT00274677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Experimental treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamotrigine
Description: Experimental treatment
Study: NCT03250208

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the control group will receive a placebo containing no active ingredients
Study: NCT00685789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture, deqi
Description: Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture Non-manipulation
Description: After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
Study: NCT02356289

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461
Study: NCT02681289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early goal directed neuromotor therapy
Description: Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early goal directed neuromotor therapy
Description: Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
Study: NCT00635882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol 100/10 mcg
Description: mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol 200/10 mcg
Description: mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol 400/10 mcg
Description: mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF DPI 200 mcg
Description: MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF MDI 200 mcg
Description: MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MF/F MDI placebo twice daily (BID) (2 inhalations)
Study: NCT06293768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)
Description: Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)
Description: Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
Study: NCT01380834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
Study: NCT02702115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-318
Description: A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
Study: NCT00957736

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
Study: NCT02038257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide Laser
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
Study: NCT03093259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464 is a new Anti-inflammatory drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo matching with ABX464
Study: NCT01380834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment group
Description: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
Study: NCT04659525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study: NCT01304056

Intervention type: DEVICE
Intervention: Ventilatory therapy
Study: NCT01395927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
Study: NCT03267212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Non-invasive ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
Study: NCT01893515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-4016
Study: NCT03328741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Osteoarthritis treatment
Description: 6 week online-program
Study: NCT01893515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02934243

Intervention type: DEVICE
Intervention: laryngeal mask insertion
Description: airway management with laryngeal mask

Intervention type: DEVICE
Intervention: laryngeal mask insertion
Description: airway management with laryngeal mask
Study: NCT03437408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping and ablation
Description: High density substrate map. Data collection during ablation
Study: NCT01311687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 4 mg pomalidomide capsules administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally
Study: NCT03328741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face osteoarthritis treatment
Description: 3 months face-to-face program
Study: NCT02605720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
Study: NCT04926129

Intervention type: OTHER
Intervention: Other: Assessments
Description: Administered as specified in the treatment arm.

Intervention type: OTHER
Intervention: Other: Assessments
Description: Administered as specified in the treatment arm.
Study: NCT03249532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
Study: NCT02107781

Intervention type: DEVICE
Intervention: AbViser abdominal compartment pressure measuring device
Description: AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
Study: NCT03249532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cool hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cool hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cool hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
Study: NCT00919295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04076163

Intervention type: OTHER
Group type: OTHER
Intervention: serious game
Description: a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
Study: NCT02263287

Intervention type: OTHER
Group type: OTHER
Intervention: LeSCoD scale
Description: LeSCoD is a clinical scale

Intervention type: OTHER
Group type: OTHER
Intervention: LeSCoD scale
Description: LeSCoD is a clinical scale

Intervention type: OTHER
Group type: OTHER
Intervention: LeSCoD scale
Description: LeSCoD is a clinical scale
Study: NCT03889886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (0.1%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (1.0%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (3.0%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study: NCT02556957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthScouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT02421055

Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-Y Gastric Bypass

Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Study: NCT04662814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shock wave therapy
Description: Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary modification
Description: Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary modification
Description: Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
Study: NCT04659525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study: NCT01185795

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Description: yogurt, twice per day (BID), 6 weeks
Study: NCT03222843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: once daily
Study: NCT04318015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: All treatment will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: All treatment will be administered orally.